# HYDROXAMATES

## Claims
Verwendung einer Verbindung mit der Struktur in der R¹ ein Wasserstoffatom, einen Niederalkyl , Aryl , Niederalkenyl , Cycloalkyl oder Aralkylrest oder die Gruppe bedeutet, in der n 1 bis 4 beträgt und X eine Hydroxygruppe, einen Alkoxyrest, eine Aminogruppe, einen C₁ C₄ Alkylaminorest oder einen C₁ C₄ Dialkylaminorest bedeutet R₂ ein Wasserstoffatom oder einen Niederalkylrest darstellt R³ einen C₁ C₂₀ Alkyl , C₃ C₂₀ Alkenyl , Aryl , Arylalkyl , Cycloalkyl , Arylalkenyl , Niederalkoxy , Niederalkenyloxy , Arylalkoxy oder Cycloalkyloxyrest darstellt und m 1 bis 5 beträgt oder einer solchen Verbindung in Form eines pharmazeutisch Verträglichen ein oder zweibasigen Salzes, wobei Niederalkyl oder Alkyl allein oder als Teil eines anderen Restes , sofern nicht anders bestimmt, einen gerad oder verzweigtkettigen Rest mit bis zu 12 Kohlenstoffatomen, bedeutet, sowie derartige Reste mit Halogensubstituenten, Wie Fluor , Brom , Chlor oder Jodatome oder die Gruppe CF₃ , einem Alkoxysubstituenten, einem Arylsubstituenten, einem Alkylarylsubstituenten, einem halogenierten Arylsubstituenten, einem Cycloalkylsubstituenten, einem Alkylcycloalkylsubstituenten, einer Hydroxygruppe, einem Alkylaminosubstituenten, einem Alkanoylaminosubstituenten, einem Arylcarbonylaminosubstituenten, einem Nitrosubstituenten, einem Cyanosubstituenten oder einem Alkylthiosubstituenten wobei Cycloalkyl allein oder als Teil eines anderen Restes einen gesättigten cyclischen Kohlenwasserstoffrest mit 3 bis 12 Kohlenstoffatomen bedeutet, wobei die Reste mit 1 oder 2 Halogenatomen, 1 oder 2 Niederalkylresten, 1 oder 2 Niederalkoxyresten, einem Arylrest, 1 oder 2 Hydroxygruppen, 1 oder 2 Alkylaminoresten, 1 oder 2 Alkanoylaminoresten, 1 oder 2 Arylcarbonylaminoresten, 1 oder 2 Aminogruppen, 1 oder 2 Nitrogruppen, 1 oder 2 Cyanogruppen oder 1 oder 2 Alkylthioresten substituiert sein können wobei Aryl allein oder als Teil eines anderen Restes einen ein oder zweikernigen aromatischen Rest mit 6 bis 10 Kohlenstoffatomen im Ringanteil bedeutet, einschließlich substituierter Phenyl oder substituierter Naphthylgruppen, wobei der Substituent entweder der Phenyloder der Naphthylgruppe 1 oder 2 Niederalkylreste, 1 oder 2 Halogenatome Chlor, Brom oder Fluor , 1 oder 2 Niederalkoryreste, 1 oder 2 Hydroxygruppen, 1 oder 2 Alkylaminoreste, 1 oder 2 Alkanoylaminoreste, 1 oder 2 Arylcarbonylaminoreste, 1 oder 2 Aminogruppen, 1 oder 2 Nitrogruppen, 1 oder 2 Cyanogruppen und oder 1 oder 2 Alkylthioreste bedeuten kann wobei Alkenyl allein oder als Teil eines anderen Restes , sofern nicht anders bestimmt, einen ungesättigten Kohlenwasserstoffrest mit 3 bis 8 Kohlenstoffatomen und einer einfachen Kohlenstoff Kohlenstoff Doppelbindung bedeutet und wobei die Reste CH₂ m und CH₂ n gerad oder verzweigtkettige Reste im Falle von CH₂ m mit 0 bis 5 Kohlenstoffatomen in der Hauptkette, und im Falle von CH₂ m mit 1 bis 4 Kohlenstoffatomen in der Hauptkette einschließen und einen oder mehrere Niederalkyl oder Halogensubstituenten enthalten können zur Herstellung eines Arzneimittels zur Behandlung von Allergien.

## Description
The present invention relates to the use of hydroxamates as inhibitors of Δ⁵ lipoxygenase and thus as antiallergy agents. These compounds have the structural formula wherein R¹ is hydrogen, lower alkyl, aryl, lower alkenyl, cycloalkyl, aralkyl or wherein n is 1 to 4 and X is hydroxy, lower alkoxy, amino C₁ C₄ alkylamino or C₁ C₄ dialkylamino R² is hydrogen or lower alkyl and R³ is C₁ C₂₀ alkyl, C₃ C₂₀ alkenyl, aryl, aryl alkyl, cycloalkyl, aryl alkenyl, alkoxy, lower alkenyloxy, aryl alkoxy or cycloalkyloxy and m is 0 to 5. Such compounds where R² is lower alkyl are novel compounds. Also novel are N hydroxy N methyl 1,1 biphenylyl 4 acetamide, N 1,1 dimethylethyl N hydroxy 1,1 biphenylyl 4 acetamide, N hydroxy N phenylbenzenebutanamide, N hydroxy N phenylmethyl cyclohexane acetamide, N hydroxy N phenylmethyl benzenebutanamide and N hydroxy N pentylbenzenebutanamide. Where R¹ is and R² is H, the above compounds may form binary or dibasic salts such as with alkali metal, such as a dilithium, disodium or dipotassium salt where R¹ is other than and R² is H, the above compounds will form only a monobasic salt. In addition, the compounds of formula I will form salts with dicyclohexylamine or other amines as well as with tris hydroxymethyl aminomethane, glucamine and other amines. The term lower alkyl or alkyl as employed herein by itself or as part of another group includes both straight and branched chain radicals of up to 12 carbons, preferably l to 8 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4 dimethylpentyl, octyl, 2,2,4 trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups including a halo substituent, such as F, Br, Cl or I or CF₃, an alkoxy substituent, an aryl substituent, an alkyl aryl substituent, a haloaryl substituent, a cycloalkyl substituent, an alkylcycloalkyl substituent, hydroxy, an alkylamino substitutent, an alkanoylamino substituent, an arylcarbonylamino substituent, a nitro substituent, a cyano substituent, a thiol substituent or an alkylthio substituent. The term C₁ C₂₀ alkyl as employed herein includes the above alkyl radicals of l to 8 carbons and more as well as alkyl radicals of up to and including 20 carbon atoms, preferably from 4 to 16 carbons, such as in addition to the C₄ to C₁₂ alkyl radicals set out above, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosanyl including all isomers thereof with or without the above substituents. The term cycloalkyl employed herein by itself or as part of another group includes saturated cyclic hydrocarbon groups containing 3 to 12 carbons, preferably 3 to 8 carbons, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, any of which groups may be substituted with 1 or 2 halogens, 1 or 2 lower alkyl groups, 1 or 2 lower alkoxy groups, an aryl group, 1 or 2 hydroxyl groups, 1 or 2 alkylamino groups, 1 or 2 alkanoylamino groups, 1 or 2 arylcarbonylamino groups, 1 or 2 amino groups, 1 or 2 nitro groups, 1 or 2 cyano groups, 1 or 2 thiol groups and 1 or 2 alkylthio groups. The term aryl or Ar as employed herein by itself or as part of another group refers to monocyclic or bicyclic aromatic groups containing from 6 to 10 carbons in the ring portion, such as phenyl, naphthyl, substituted phenyl or substituted naphthyl wherein the substituent on either the phenyl or naphthyl may be 1 or 2 lower alkyl groups, 1 or 2 halogens Cl, Br, or F , 1 or 2 lower alkoxy groups, 1 or 2 hydroxyl groups, 1 or 2 alkylamino groups, 1 or 2 alkanoylamino groups, 1 or 2 arylcarbonylamino groups, 1 or 2 amino groups, 1 or 2 nitro groups, 1 or 2 cyano groups, 1 or 2 thiol groups and or 1 or 2 alkylthio groups. The term aralkyl , aryl alkyl or aryl lower alkyl as used herein refers to lower alkyl groups as discussed above having an aryl substituent, such as benzyl. The term lower alkenyl or alkenyl as employed herein by itself or as part of another group includes an unsaturated hydrocarbon group having from 3 to 8 carbons and a single carbon carbon double bond, such as ethenyl, 1 propenyl, 2 propenyl, 1 butenyl, 2 butenyl, 3 butenyl and the like. The term C₃ C₂₀ alkenyl includes straight or branched chain radicals of from 3 to 20 carbons, preferably 4 to 16 carbons in the normal chain, which include one double bond in the normal chain, such as any of the lower alkenyl grups mentioned above as well as 2 hexenyl, 3 hexenyl, 2 heptenyl, 3 heptenyl, 4 heptenyl, 3 octenyl, 3 nonenyl, 4 decenyl, 3 undecenyl, 4 dodecenyl, 2 tridecenyl, 3 tetradecenyl, 1 pentadecenyl, 2 hexadecenyl, 4 heptadecenyl, 7 octadecenyl, 6 nonadecenyl and 8 eicosenyl, 2,5 hexadienyl, 3,7 octadienyl, 2,6 decadienyl, 3,9 pentadecadienyl, 4,12 nonadecadienyl, including all isomers thereof and the like. The term aryl alkenyl as used herein refers to lower alkenyl groups as discussed above having an aryl substituent. The term lower alkoxy , alkoxy , lower alkenyloxy , cycloalkoxy or aralkoxy includes any of the above lower alkyl, alkyl, lower alkenyl, cycloalkyl or aralkyl groups linked to an oxygen atom. The term alkanoyl as used herein by itself or as part of another group refers to a lower alkyl group linked to a carbonyl group. The term halogen or halo as used herein refers to chlorine, bromine, fluorine or iodine with chlorine being preferred. The terms CH₂ Preferred are those compounds of the invention wherein m is 1, 2 or 3, R¹ is alkyl, such as methyl, pentyl, phenyl or phenylalkyl, R² is H and R³ is biphenyl, cycloalkyl or phenyl. The various compounds of the invention may be prepared as described below. Compounds of formula I wherein R² is H may be prepared as follows. The acid of the structure is subjected to a coupling reaction by reacting The hydroxamate II is then reacted with halide wherein X is lower alkoxy in the final product at a temperature within the range of about 50 to about 110 C, employing a molar ratio of The protected compound III where the protecting group is benzyl is then subjected to hydrogenolysis and hydrogenation by treating compound III with hydrogen in the presence of a palladium hydroxide on carbon catalyst to form the compounds of the invention IV wherein R¹ is CH₂ the ester group in IV may be removed by treating with an alkali metal hydroxide such as lithium hydroxide in an organic solvent such as dioxane or methanol. Where R¹ in the final product is to be that is, n is 1, and X is OH or alkoxy, then the protected compound II will be reacted with allyl bromide BrCH₂CH CH₂ to form the intermediate IIIa which is then treated with ozone, Jones reagent H₂CrO₄ H₂SO₄ H₂O and diazomethane to form the ester IIIb Ester IIIb may then be subjected to hydrogenolysis as described above to form the ester IVa of the invention which may then be hydrolyzed to the corresponding acid IVb. Where it is desired to form compounds wherein R³ C₃ C₂₀ is alkenyl or aryl alkenyl and or R¹ is lower alkenyl, the protecting group where the protecting group is either tetrahydropyanyl or methoxymethyl may be removed by treating III or IIIb with acetic acid without reducing the double bond in the R³ group and or in the R¹ group. Alternatively, when the protecting group is methylthiomethyl, it can be removed by treatment with CuO CuCl₂ in aqueous acetone without reducing the double bond in the R³ group or in the R¹ group. Where it is desired to prepare compounds of the invention wherein R¹ is and X is amino, alkylamino or dialkylamino wherein each alkyl of the dialkyl group is the same or different , then compound III wherein R¹ is is hydrolyzed to the corresponding acid IIIA by reacting III with lithium hydroxide in the presence of a solvent such as dioxane as described above The acid IIIA is then treated with an activating agent such as isobutylchloroformate, organic base such as triethylamine and inert organic solvent such as acetonitrile and reacted with ammonium hydroxide where X is amino or with an appropriate alkylamine or dialkylamine where X is alkylamino or dialkylamino, respectively, to form amide IIIB Compound IIIB where the protecting group is benzyl may then be subjected to hydrogenolysis and hydrogenation as described above to form IVA Compound IIIB where the protecting group is tetrahydropyranyl may also be treated with acetic acid to remove the protecting group to form the corresponding compound wherein R³ is alkenyl. Compounds of the invention wherein R¹ is hydrogen may be prepared by removing the protecting group of compound II, for example, by treating II, where the protecting group is tetrahydropyranyl, with an acid catalyst such as pyridinium p toluene sulfonate in the presence of an alcoholic solvent such as methanol, to form IIA wherein R² is hydrogen Compound IIA may be reduced as described above to form the corresponding compound wherein R³ is C₃ to C₂₀ alkyl. Preparation of compounds of formula IIA wherein R² is alkyl, that is compound V, is described hereinafter. Compounds of the invention wherein R² is alkyl and R³ is C₁ C₂₀ alkyl or aryl alkyl may be prepared by subjecting acid The hydroxamate V is then reacted with halide Compound VI may be reduced as described above to form the corresponding compound wherein R³ is C₃ C₂₀ alkyl and or may be hydrolyzed where R¹ is to form the corresponding acid. Compounds of formula I wherein R² is H may also be prepared by treating the acid with oxalyl chloride in the presence of an inert organic solvent such as benzene, ethyl ether or tetrahydrofuran under an inert atmosphere such as argon to form the corresponding acid chloride which is then reacted with hydroxylamine in the presence of an inert organic solvent such as tetrahydrofuran and in an organic base such as triethylamine to form the compounds of the invention IIA Compounds of formula I wherein R² is alkyl may be prepared from compound IIA by treating IIA with a base such as sodium hydride and an alkyl halide Hal Alkyl in the presence of an inert organic solvent such as tetrahydrofuran and dimethylformamide, to form compounds of the invention VIA In an alternative method, compounds of formula I of the invention may be prepared by subjecting acid wherein the protecting group is C₆H₅CH₂, CH₃SCH₂, or tetrahydropyranyl and the like and M is an alkali metal such as Li, Na or K, or M is tetrabutylammonium, dissolved in an inert organic solvent such as dioxane, acetone, dimethylformamide or acetonitrile, in the presence of an activating agent such as isobutylchloroformate, an organic base such as triethylamine, and an inert organic solvent such as acetone, dioxane, dimethylformamide or acetonitrile. The coupling reaction is carried out at temperatures within the range of about 15 to about 25 C, employing a molar ratio of IX A within the range of about 1 1 to about 3 1, to form the intermediate acid of the structure X The acid X is then esterified, for example, by reacting X with a diazoalkane, such as diazomethane in ether, to form the ester XI The ester XI is then subjected to a deprotecting procedure wherein XI is treated with cupric oxide and cupric chloride in an aqueous organic solvent mixture such as aqueous acetone in the case where the protecting group is CH₃SCH₂ or XI is treated with H₂ in the presence of a palladium hydroxide on carbon catalyst in the case where the protecting group is C₆H₅ CH₂ the deprotected compound is then immediately hydrolyzed by treatment with lithium hydroxide or other base in the presence of an inert organic solvent such as dioxane, methanol or acetonitrile to form the acid compound of the invention of the structure XII The amine salt IX may be prepared from the hydroxylamine of the structure in the presence of 2,6 lutidine and methylene choride to form the compound Compound For the preparation of the lactam where the protecting group is CH₃SCH₂, the lactam Lactam XIII can be treated with a protecting compound Either The starting acid compounds The compounds of the invention are delta 5 lipoxygenase inhibitors and prevent leukotriene C₄ formation in macrophages Samuelsson, B., Science, Vol. 220, p. 568 575, 1983 . The administration of compounds of this invention to humans or animals provides a method for treating allergy of a reagin or non reagin nature. Asthma is preferably treated but any allergy wherein leukotrienes are thought to be involved as pharmacological mediators of anaphylaxis can be treated. For example, the compounds of this invention can be used for treatment of such conditions as allergic rhinitis, food allergy and urticaria as well as asthma. An effective but essentially non toxic quantity of the compound is employed in treatment. The compounds of the invention can be administered orally or parenterally to various mammalian species known to be subject to such maladies, e.g., humans, cats, dogs, and the like in an effective amount within the dosage range of about 1 to 100 mg kg, preferably about 1 to 50 mg kg and especially about 2 to 25 mg kg on a regimen in single or 2 to 4 divided daily doses. The active substance can be utilized in a composition such as tablet, capsule, solution or suspension containing about 5 to about 500 mg per unit of dosage of a compound or mixture of compounds of formula I. They may be compounded in conventional matter with a physiologically acceptable vehicle or carrier, excipient, binder, preservative, stabilizer, flavor, etc. as called for by accepted pharmaceutical practice. Also as indicated in the discussion above, certain members additionally serve as intermediates for other members of the group. The following Examples represent preferred embodiments of the invention. Unless otherwise indicated, all temperatures are expressed in C. TLC plates were visualized by spraying and heating with 5 phosphomolybdic acid in ethanol. HP 20 refers to a high porous divinylbenzene polystyrene polymer resin. To a stirring solution of 1,1 biphenylmethyl carboxylic acid 1.0 g, 4.7 mmol in 10 ml of dry benzene, under argon, was added oxalyl chloride 0.41 ml, 2.0 eq. . To this solution was added dimethylformamide dropwise in 10 minute intervals, until no gas was evolved and the solution turned slightly cloudy 2 drops . The mixture was stirred for 1 hour, then reduced on the rotovap without heating. The crude product was diluted with 5 ml of tetrahydrofuran and added dropwise to a 0 C solution of N methylhydroxylamine hydrochloride 785 mg, 2 eq. in 20 ml of THF H₂O 1 1 with triethylamine 1.93 ml, 3.0 eq. . The solution was stirred for 0.5 hour at 0 C then allowed to warm to room temperature and stir overnight. The reaction mixture was diluted with EtOAc and the organic layer was washed with H₂O, 1 To a stirring solution of 1,1 biphenyl methylcarboxylic acid 500 mg, 2.36 mmol in 10 ml of dry benzene under argon, was added oxalyl chloride 0.23 ml, 2.0 eq. . To this solution was added dimethylformamide dropwise in 10 minute intervals, until no gas was evolved and the solution turned slightly cloudy 2 drops . The mixture was stirred for 1 hour, then reduced on the rotovap without heating. The crude product, a white solid, was dissolved in 5 ml tetrahydrofuran and added dropwise to a 0 C solution of N t butylhydroxylamine hydrochloride 593 mg, 2 eq. in 20 ml of THF H₂O 1.1 with triethylamine 1.0 ml, 3.0 eq. . The solution was stirred for 1 hour at 0 C, then allowed to warm to room temperature and stir overnight. The reaction mixture was diluted with EtOAc and the organic layer was washed with H₂O, 1 To a stirring solution of 3 phenylpropylcarboxylic acid 500 mg, 3.1 mmol in 10 ml of dry benzene under argon was added oxalyl chloride 0.30 ml, 1.1 eq. . To this solution was added dimethylformamide dropwise in 10 minute intervals, until no gas was evolved and the solution turned slightly cloudy 2 drops . The mixture was stirred for 1 hour then reduced on the rotovap without heating. The crude product was diluted with 5 ml of tetrahydropyran and added dropwise to a 0 C solution of N phenylhydroxylamine 666 mg, 2 eq. in 20 ml of THF H₂O 1 1 with triethylamine 0.85 ml, 2.0 eq. . The solution was stirred for 1 hour at 0 C then allowed to warm to room temperature and stir overnight. The reaction mixture was diluted with EtOAc and the organic layer was washed with H₂O, 1 With gentle heating N hydroxyphthalimide 10.0 g, 61.4 mM was dissolved in dry CH₂Cl₂ 70 ml and dioxane 80 ml , then dihydropyran 6.16 ml, 67.6 mM, 1.1 eq and p toluenesulfonic acid monohydrate 200 mg, 2 by weight were added and the mixture stirred for 2 hours at room temperature under argon. The mixture was then washed successively with saturated NaHCO₃ 2X and brine, dried over anhydrous Na₂SO₄ and evaporated to a white solid. The solid was triturated with hexane and filtered to give 13.43 g 89 of O tetrahydropyranyl hydroxyphthalimide as a white solid m.p. 123 125 C with consistent NMR 60 MHz, CDCl₃ spectral data. TLC 1 1 EtOAc Hex, R To a stirred solution of the O THP hydroxyphthalimide 13.0 g, 52.6 mM in dry benzene 30 ml was added methyl hydrazine 2.82 ml, 53.0 mM and the mixture heated at 80 C for 15 minutes under argon. The mixture was concentrated to a 50 ml volume then vacuum distilled to give 5.46 g 89 of the desired THP hydroxylamine as a clear colorless oil with b.p. 70 C 10 mm Hg . To a 0 C solution of cyclohexanemethylcarboxylic acid 1.0 g, 7.0 mmol in 40 ml of CH₂Cl₂ under argon was added O tetrahydropyran 2 ylhydroxylamine 1.64 g, 2.0 eq. , 1 hydroxybenzotriazole 1.14 g, 1.2 eq. , N,N dicyclohexylcarbodiimide 1.73 g, 1.2 eq. sequentially. After 0.5 hour at 0 the solution was allowed to warm to room temperature and stir under argon for 6 hours. The solution was filtered, concentrated To a stirring solution of the compound of Part B 500 mg, 2.1 mmol under argon in 10 ml of dry toluene was added NaH 1.1 eq., 55 mg . The mixture was allowed to stir for 30 minutes then benzyl bromide 0.74 ml, 3.0 eq. was added. The mixture was heated to reflux and allowed to stir for 2 hours. The reaction was cooled and diluted with EtOAc and partitioned over 5 KHSO₄. The organic phase was washed with brine, dried over anhydrous MgSO₄ and evaporated to yield yellow oil which was chromatographed on LPS 1 silica gel eluting with 9 1 hexane EtOAc. Product containing fractions were evaporated to give title compound 560 mg, 82 as a pale yellow oil. TLC 9 1 hexane EtOAc. R To a stirring solution of the compound of Part C 560 mg, 1.7 mmol in 10 ml of CH₃OH under argon was added pyridinium p toluenesulfonate 510 mg 1.2 eq. . The solution was heated to 60 C in an oil bath for 24 hours. The solution was diluted with EtOAc and washed with 10 ml of brine, diluted with 10 ml of water. The organic layer was washed with brine 10 ml and dried over MgSO₄ anhydrous and reduced To a 0 C solution of 3 phenylpropyl carboxylic acid 1.0 g, 6.1 mmol in 40 ml of CH₂Cl₂ under argon was added H₂N OTHP 1.43 mg, 2.0 eq. , 1 hydroxybenzotriazole 987 mg, 1.2 eq. , N,N dicyclohexylcarbodiimide 1.51 g, 1.2 eq. sequentially. After 0.5 hour at 0 , the solution was allowed to warm to room temperature and stir under argon for 4 hours. The solution was filtered, concentrated To a stirring solution of Part A compound 520 mg, 197 mmol under argon in 10 ml of dry toluene was added NaH 1.1 eq., 52 mg . The mixture was allowed to stir for 30 minutes, then benzyl bromide 0.71 ml, 3.0 eq. was added. The mixture was heated to reflux and allowed to stir for 2 hours. The reaction was cooled and diluted with EtOAc and partitioned over 5 KHSO₄. The organic phase was washed with brine, dried over anhydrous Na₂SO₄ and evaporated to yield a yellow oil which was chromatographed on LPS 1 silica gel eluting with 4 1 hexane EtOAc. Product containing fractions were evaporated to give title compound 550 mg, 79 as a pale yellow oil. TLC 9 1 hexane EtOAc. R To a stirring solution of Part B compound 550 mg, 1.55 mmol in 10 ml of CH₃OH under argon was added pyridinium p toluenesulfonate 391 mg, 1.0 eq. . The solution was heated to 60 C in an oil bath for 48 hours. The solution was diluted with EtOAc and washed with 10 ml of brine, diluted with 10 ml of water. The organic layer was washed with brine 10 ml and dried over MgSO₄ anhydrous and reduced To a 0 C of 3 phenylpropyl carboxylic acid 1.0 g, 6.1 mmol in 20 ml of CH₂Cl₂ under argon was added H₂N OTHP 1.43 g, 2.0 eq. , 1 hydroxybenzotriazole 987 mg, 1.2 eq. , N,N dicyclohexylcarbodiimide 1.51 g, 1.2 eq. sequentially. The solution was allowed to warm to room temperature and stir under argon for 4 hours. The solution was filtered, concentrated To a stirring solution of Part A compound 610 mg, 2.3 mmol under argon in 15 ml of dry toluene was added NaH 1.1 eq., 61 mg . The mixture was allowed to stir for 30 minutes then pentyl bromide 0.86 ml, 3.0 eq. was added. The mixture was heated to reflux and allowed to stir overnight. The reaction was cooled and diluted with EtOAc and partitioned over 5 KHSO₄. The organic phase was washed with brine, dried over anhydrous MgSO₄ and evaporated to yield yellow oil which was chromatographed on LPS 1 silica gel eluting with 8 2 hexane EtOAc. Product containing fractions were evaporated to give title compound 480 g as an oil. TLC 1 1 hexane EtOAc. R To a stirring solution of Part B compound 480 mg, 1.44 mmol in 15 ml of CH₃OH under argon was added pyridinium To a stirred solution of the 1 decenyl carboxylic acid 2.00 g, 11.64 mM in dry CH₂Cl₂ C, 71.10 35 ml is added 1 hydroxybenzotriazole 1.89 g, 13.97 mM, 1.2 eq. and N,N dicyclohexylcarbodiimide 2.88 g, 13.97 mM, 1.2 eq. . After one hour at room temperature under argon, O benzylhydroxylamine hydrochloride 4.64 g, 29.1 mM, 2.5 eq. and Et₃N 4.06 ml, 29.1 mM, 2.5 eq. are added and the mixture stirred for an additional two hours. The crude mixture is filtered 2X , evaporated, taken up in ethyl acetate, filtered again and then washed successively with 5 KHSO₄, saturated NaHCO₃, and brine. Concentration To a solution of the title A benzylhydroxamate 496 mg, 1.80 mM in dry toluene 5 ml is added prewashed NaH 45 mg, 1.80 mM and the mixture stirred for 20 minutes at room temperature under argon. Excess methyl iodide 0.313 ml, 4.92 mM, 3 eq is added and the mixture is refluxed for 5 hours, then cooled and partitioned between 5 KHSO₄ and ethyl acetate. The organic phase is washed with brine, dried over anhydrous Na₂SO₄ and evaporated to a yellow oil which was chromatographed on Whatman LPS 1 silica gel eluting with 3 2 pet ether ether. Product containing fractions are evaporated to give the title N methylated product. Argon is bubbled through a solution of the title B N methylhydroxamate 600 mg in CH₃OH 10 ml for 5 minutes before adding 20 palladium hydroxide on carbon 100 mg, 15 by weight and stirring under H₂ for 2 hours. The mixture is then filtered through Celite, evaporated, taken up in EtOAc, filtered through a small plug of Whatman LPS 1 silica gel and evaporated to an off white crystalline solid. Recrystallization from EtOAc Hex gives desired title product. To a solution of 1 decenylcarboxylic acid 0.66 g, 3.84 mM in dry CH₂Cl₂ 15 ml is added 1 hydroxybenzotriazole 623 mg, 4.61 mM, 1.2 eq and DCC 951 mg, 4.61 mM, 1.2 eq and the mixture stirred for one hour under argon at room temperature. O THP hydroxylamine 900 mg, 7.68 mM, 2 eq is added and the mixture stirred for 3 hours at room temperature. The mixture is filtered, evaporated, taken up in ethyl acetate, filtered again, evaporated and chromatographed on Whatman LPS 1 silica gel eluting with 8 2 Hex EtOAc. Product containing fractions are evaporated to give title coupled product. Prewashed NaH 70 mg, 2.9 mM, 1.2 eq is added to a solution of the title A THP hydroxamate 622 mg, 2.42 mM in dry toluene 10 ml and the mixture stirred at room temperature under argon for 15 minutes. Ethyl 4 iodobutyrate 1.76 g, 7.26 mM, 3 eq is added and the mixture is refluxed overnight. The mixture is partitioned between 5 KHSO₄ and EtOAc, the organic phase washed with brine, dried over anhydrous Na₂SO₄ and evaporated to an oil. The crude oil is run through neutral alumina act 1 to remove any remaining starting material eluting with 8 2 Hex Acetone. Product fractions are evaporated and then chromatographed on Whatman LPS 1 silica gel eluting with 95 5 Hex Acetone. Product fractions are evaporated to give the desired title N alkylated product. A stirred mixture of the title B O THP hydroxamate 816 mg, 2.20 mM in 3 2 2 HOAc THF H₂O 6 ml is heated at 55 C overnight under argon. The mixture is then carefully partitioned between saturated NaHCO₃ and EtOAc, the organic layer washed with brine, dried over anhydrous Na₂SO₄ and evaporated to give the desired title hydroxamic acid. To a solution of the title C crude ethyl ester 879 mg in dioxane 10 ml is added a 1.0 N LiOH solution 4.4 ml and the mixture stirred for 1.5 hours at room temperature under argon. The mixture is then partitioned between 5 KHSO₄ and EtOAc, the organic phase washed with brine, dried over anhydrous Na₂SO₄ and evaporated to a solid. One recrystallization from EtOAc Hex gives the desired hyroxamic acid. Argon was bubbled through a solution of the Example 8 title C hydroxamate 357 mg, 1 mM in absolute EtOH 15 ml for 5 minutes before adding 20 palladium hydroxide on carbon 59 mg and shaking the mixture under H₂ on a Parr apparatus for 7 hours. The mixture is filtered through a layered plug of Celite and Whatman LPS 1 silica gel and evaporated to give the desired title hydroxamic acid. To a stirred solution of the Example 9 methyl ester 357 mg, 1 mM in dioxane 4 ml is added a 1.0N LiOH solution 2.6 ml, 2.6 mM and the mixture stirred under argon for 3 hours. The mixture is diluted with H₂O, extracted with ether to remove a non polar impurity , the aqueous layer acidified to pH 2 with 1.0N HCl and then re extracted with ethyl acetate. The organic phase is washed with brine, dried over anhydrous Na₂SO₄ and evaporated to an oil. The crude oil is dissolved in 1.0N LiOH 3 ml and chromatographed on HP 20 eluting with a gradient of neat H₂O 50 50 H₂O CH₃CN. Product containing fractions are combined and lyophilized to give the desired title product. Prewashed sodium hydride 188 mg, 7.5 mM, 1.1 eq. is added to a solution of hydroxamate prepared in Example 7 Part A 2.00 g, 6.84 mM in dry toluene 14 ml and the mixture stirred at room temperature under argon for 15 minutes. Ethyl 4 iodobutyrate 3.31 g, 13.68 mM, 2.0 eq. is then added and the mixture refluxed overnight. The crude mixture is cooled, partitioned between 5 KHSO₄ and EtOAc, the organic layer washed with brine, dried over anhydrous Na₂SO₄ and evaporated to an oil. The oil is dissolved in CH₂Cl₂ and flash chromatographed on Whatman LPS 1 silica gel eluting with 3 2 pet ether ether. Product containing fractions are evaporated to give the desired title alkylated product. Argon is bubbled through a solution of the title A hydroxamate 407 mg, 1 mM in absolute ethanol 10 ml for 5 minutes before adding 20 palladium hydroxide on carbon 58 mg , and stirring under H₂ for 4 hours. The mixture is then filtered through a layered plug of Celite over LPS 1 silica gel, evaporated to a solid and recrystallized from EtOAc Hex to give the desired title hydroxamic acid To a solution of 1 decenyl carboxylic acid 1.32 g, 7.68 mM in dry CH₂Cl₂ 20 ml is added 1 hydroxybenzotriazole 1.25 g, 9.22 mM, 1.2 eq. and N,N dicyclohexylcarbodiimide 1.90 g, 9.22 mM, 1.2 eq. and the mixture stirred for 1 hour at room temperature. Methoxylamine hydrochloride 1.28 g, 15.36 mM. 2 eq. and triethylamine 2.14 ml, 15.36 mM, 2 eq. are added, the mixture stirred for 3 hours at room temperature, then filtered, evaporated, taken up in ethyl acetate and filtered again. The organic phase is washed successively with 5 KHSO₄, saturated NaHCO₃ and brine, then dried over anhydrous Na₂SO₄ and evaporated to an oil. The crude oil is flash chromatographed on LPS 1 silica gel eluting with 7 3 hexane ethyl acetate. Product containing fractions are evaporated to give the desired title product. To a solution of the title A methyl hydroxamate 328 mg, 1.52 mM in dry toluene 6 ml is added prewashed NaH 38 mg, 1.52 mM and the mixture stirred for 20 minutes at room temperature. Ethyl 4 iodobutyrate 668 mg, 2.76 mM is added and the mixture is refluxed overnight under argon. The mixture is cooled, partitioned between 5 KHSO₄ and ethyl acetate and the organic phase washed with brine, dried over anhydrous Na₂SO₄ and evaporated to an oil. The crude oil is flash chromatographed on LPS 1 silica gel eluting with 3 2 petroleum ether Et₂O. Product containing fractions are evaporated to give the desired title N alkylated product. To a solution of the title B ethyl ester 660 mg, 2 mM in dioxane 10 ml is added 1.0N LiOH 2.20 ml and the mixture stirred at room temperature under argon for two hours. The mixture is then partitioned between 5 KHSO₄ and ethyl acetate, the organic phase washed with brine, dried over anhydrous Na₂SO₄ and evaporated to an oil. Crude oil is flash chromatographed on LPS 1 silica gel eluting successively with 85 15 Hex Acetone and 95 5 CH₂Cl₂ CH₃OH. Product containing fractions are evaporated to give the title acid. The dicyclohexylamine salt is prepared by dissolving the title C acid in EtOAc 1 ml and treating it with dicyclohexylamine 126 µl, 1.1 eq. . The mixture is evaporated and then crystallized from cold petroleum ether to give the title methyl hydroxamate as the dicyclohexylamine salt. To a solution of the ethyl ester prepared as described in Example 11 Part A 814 mg, 2 mM in dioxane 5 ml is added 1.0N LiOH 2.3 ml and the mixture stirred for 3 hours under argon at room temperature. The mixture is then partitioned between 5 KHSO₄ and EtOAc, the organic layer washed with brine, dried over anhydrous Na₂SO₄ and evaporated to give the title acid. To a solution of the title A acid 379 mg, 1 mM and Et₃N 181 µl, 1.3 mM in dry CH₃CN 5 ml is added isobutylchloroformate 169 µl, 1.3 mM and the mixture stirred for 1 hour at room temperature under argon. Concentrated NH₄OH 3 ml is added dropwise, the mixture is stirred for 30 minutes, then it is partitioned between 1.0N HCl and EtOAc. The organic layer is washed with brine, dried over anhydrous Na₂SO₄ and evaporated to an oil. The crude oil is chromatographed on alumina neutral activity 2 with 1 1 EtOAc Hex and 9 1 CH₂Cl₂ CH₃OH followed by a chromatography on Whatman LPS 1 silica gel eluting with neat EtOAc. Product containing fractions are evaporated to give the title amide. Argon is bubbled through a solution of the title B hydroxamate 290 mg in CH₃OH 5 ml for 5 minutes before adding 20 palladium hydroxide on carbon 35 mg, 12 by weight and stirring under H₂ for 2 hours. The mixture is filtered through Celite, evaporated, taken up in EtOAc, filtered through anhydrous MgSO₄ powder and evaporated to an off white solid. Two recrystallizations from EtOAc Hex, then acetone Hex give the title amide. Prewashed NaH 51 mg, 2.11 mM, 1.1 eq. is added to a solution of the hydroxamate prepared as described in Example 7 Part A 562 mg, 1.92 mM in dry toluene 10 ml and the mixture stirred for 20 minutes at room temperature under argon. Ethyl 5 iodovalerate 1.48 g, 5.76 mM, 3 eq. is added and the mixture refluxed overnight. The mixture is then partitioned between 5 KHSO₄ and EtOAc, the organic layer washed with brine, dried over anhydrous Na₂SO₄ and evaporated to an oil. The remaining starting material is removed by chromato graphing on neutral alumina act. 1 eluting with 1 1 petroleum ether. Product fractions are evaporated, then flash chromatographed on Whatman LPS 1 silica gel eluting with 3 2 petroleum ether ether. Product fractions are evaporated to give the title N alkylated product. Argon is bubbled through a solution of the title A hydroxamate 421 mg in methanol 10 ml for 5 minutes, then 20 palladium hydroxide on carbon 15 mg is added and the mixture stirred under H₂ for 1 hour. The mixture is filtered through Celite, evaporated, taken up in ethyl acetate, filtered through powdered anhydrous MgSO₄ and evaporated to give the desired title hydroxamic acid. To a solution of the title B ethyl ester 331 mg, 1 mM in dioxane 8 ml is added 1.0 N LiOH 2.9 ml and the mixture stirred under argon at room temperature for 40 minutes. The mixture is then partitioned between 5 KHSO₄0 and EtOAc, the organic phase washed with brine, dried over anhydrous Na₂SO₄ and evaporated to a solid. One recrystallization from EtOAc Hex gives desired title acid. Argon is bubbled through a solution of 1 decenylcarboxylic acid 1.6 g in CH₃OH 20 ml for 5 minutes. 10 Palladium on carbon is added and the mix is shaken on a Parr apparatus for 4 hours under H₂. The mixture is filtered through Celite and evaporated to give the desired title saturated acid. To a solution of the title A acid 590 mg, 3.43 mM in dry CH₂Cl₂ 15 ml is added 1 hydroxybenzotriazole 557 mg, 4.12 mM, 1.2 eq. and N,N dicyclohexylcarbodiimide 850 mg, 4.12 mM, 1.2 eq. and the mixture stirred at room temperature under argon for 1 hour. Triethylamine 1.20 ml, 8.58 mM, 2.5 eq. and O benzylhydroxylamine hydrochloride 1.37 g, 8.58 mM, 2.5 eq. are then added and the mixture stirred for 3 hours at room temperature. The mixture is filtered, evaporated, taken up in ethyl acetate and washed successively with 5 KHSO₄ and brine then dried over anhydrous Na₂SO₄ and evaporated to a white solid. Crude solid is flash chromatographed on Whatman LPS 1 silica gel eluting with 9 1 hexane EtOAc. Product containing fractions are evaporated to give the desired title benzylhydroxamate. To a solution of the title B benzylhydroxamate 399 mg, 1.36 mM in dry toluene 6 ml is added prewashed NaH 36 mg, 1.50 mM, 1.1 eq. and the solution stirred at room temperature for 20 minutes before adding allyl bromide 294 µl, 3.4 mM, 2.5 eq. and refluxing overnight. The mixture is cooled, partitioned between 5 KHSO₄ and EtOAc, the organic layer washed with brine, dried over anhydrous Na₂SO₄ and evaporated to a yellow oil. Crude oil is chromatographed on neutral alumina act. 1 eluting with 1 1 petroleum ether ether. Product fractions are evaporated to give the title N alkylated product. The title C N alkylbenzylhydroxamate 3.34 g, 10 mM is dissolved in EtOAc, 16 ml cooled to 78 C and purged with O₂ before bubbling ozone through the solution until a pale blue color persisted. Excess ozone is purged with bubbling N₂, then the ozonide solution is treated with Jones reagent 1.0 ml at 78 C. The mixture is allowed to warm to room temperature, diluted with EtOAc and the organic phase washed successively with H₂O and brine, then dried over anhydrous Na₂SO₄ and evaporated to a crude oil. The crude oil is dissolved in Et₂O 10 ml , cooled to 0 C ice bath and treated with an ethereal solution of diazomethane. The mixture is evaporated, and chromatographed on Whatman LPS 1 silica gel eluting with 9 1 Hex EtOAc. Product fractions are evaporated to give of the desired title methyl ester. Argon is bubbled through a solution of the title D benzylhydroxamate 270 mg in CH₃OH 8 ml for 5 minutes, then 20 palladium hydroxide on carbon 32 mg, 12 by weight is added and the mixture stirred for 1 hour under H₂. The mixture is filtered through Celite, evaporated, taken up in EtOAc, filtered through anhydrous MgSO₄ and evaporated to give the title E hydroxamic acid. To a solution of the title E methyl ester 274 mg, 1 mM is dissolved in dioxane 6 ml is added 1.0N LiOH 2.16 ml, 2.16 mM and the mixture stirred for 20 minutes at room temperature under argon. The mixture is partitioned between 5 KHSO₄ and EtOAc, the organic phase washed with brine, dried over anhydrous Na₂SO₄ and evaporated to an off white solid. One recrystallization from EtOAc Hex gives the desired title acid. Following the procedure of Example 1 except substituting N propylhydroxylamine for N methylhydroxylamine, the title compound is obtained. Following the procedure of Example 1 except substituting N phenylmethyl hydroxylamine for N methylhydroxylamine, the title compound is obtained. Following the procedure of Example 1 except substituting N phenyl hydroxylamine for N methylhydroxylamine, the title compound is obtained. Following the procedure of Example 4 except substituting cyclohexyl iodide for benzyl bromide, the title compound is obtained. Following the procedure of Example 4 except substituting propyl iodide for benzyl bromide, the title compound is obtained. Following the procedure of Example 5 except substituting butyl iodide for benzylbromide, the title compound is obtained. Following the procedure of Example 5 except substituting i butyl iodide for benzyl bromide, the title compound is obtained. Following the procedure of Example 5 except substituting pentyl iodide for benzyl bromide, the title compound is obtained. Following the procedure of Example 6 except substituting hexyl iodide for pentyl bromide, the title compound is obtained. Following the procedure of Example 6 except substituting phenethyl bromide for pentyl bromide, the title compound is obtained. Following the procedure of Example 6 except substituting octyl iodide for pentyl bromide, the title compound is obtained. Following the procedure of Example 6 except eliminating Step B, the title product is obtained. Following the procedure of Example 3 except substituting N methoxyamine hydrochloride for N phenylhydroxyl amine hydrochloride, the title compound is obtained. Following the procedure of Example 7 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and substituting ethyl iodide for methyl iodide in Part B, the title compound is obtained. Following the procedure of Example 7 except substituting propoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and substituting butyl iodide for methyl iodide in Part B, the title compound is obtained. Following the procedure of Example 7 except substituting pentoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and substituting ethyl iodide for methyl iodide in Part B, the title compound is obtained. Following the procedure of Example 7 except substituting hexyloxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and substituting propyl iodide for methyl iodide in Part B, the title compound is obtained. Following the procedure of Example 7 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and substituting benzyl iodide for methyl iodide in Part B, the title compound is obtained. Following the procedure of Example 7 except substituting propoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and substituting phenethyl iodide for methyl iodide in Part B, the title compound is obtained. Following the procedure of Example 7 except substituting butoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and substituting n pentyl iodide for methyl iodide in Part B, the title compound is obtained. Following the procedure of Example 7 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and eliminating Step B, the title compound is obtained. Following the procedure of Example 7 except substituting propoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and eliminating Step B, the title compound is obtained. Following the procedure of Example 7 except substituting methoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, and eliminating Step C, the title compound is obtained. Following the procedure of Example 7 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, substituting ethyl iodide for methyl iodide in Part B, and eliminating Step C, the title compound is obtained. Following the procedure of Example 7 except substituting propoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, substituting butyl iodide for methyl iodide in Part B, and eliminating Step C, the title compound is obtained. Following the procedure of Example 7 except substituting pentoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, substituting ethyl iodide for methyl iodide in Part B, and eliminating Step C, the title compound is obtained. Following the procedure of Example 7 except substituting hexyloxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, substituting propyl iodide for methyl iodide in Part B, and eliminating Step C, the title compound is obtained. Following the procedure of Example 7 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, substituting benzyl iodide for methyl iodide in Part B, and eliminating Step C, the title compound is obtained. Following the procedure of Example 7 except substituting methoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, substituting phenethyl iodide for methyl iodide in Part B, and eliminating Step C, the title compound is obtained. Following the procedure of Example 7 except substituting methoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, substituting ethyl iodide for methyl iodide in Part B, and eliminating Step C, the title compound is obtained. Following the procedure of Example 7 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, and eliminating Steps B and C, the title compound is obtained. Following the procedure of Example 7 except substituting 1 undecenylcarboxylic acid for 1 decenylcarboxylic acid in Part A, the title compound is obtained. Following the procedure of Example 7 except substituting 1 hexenylcarboxylic acid for 1 decenylcarboxylic acid, the title compound is obtained. Following the procedure of Example 7 except substituting 1 heptenylcarboxylic acid for 1 decenylcarboxylic acid, the title compound is obtained. Following the procedure of Example 7 except substituting 1 octenylcarboxylic acid for 1 decenylcarboxylic acid, the title compound is obtained. Following the procedure of Example 7 except substituting 1 nonenylcarboxylic acid for 1 decenyl carboxylic acid, the title compound is obtained. Following the procedure of Example 7 except substituting 1 dodecenylcarboxylic acid for 1 decenylcarboxylic acid, the title compound is obtained. Following the procedure of Example 7 except substituting 1 pentadecenylcarboxylic acid for 1 decenylcarboxylic acid, the title compound is obtained. Following the procedure of Examples 7 and 13 except substituting acrylic acid for 1 decenylcarboxylic acid, the title compound is obtained. Following the procedure of Example 8 except substituting 1 hexenyl carboxylic acid for 1 decenyl carboxylic acid in Part A and substituting methyl iodide for ethyl 4 iodobutyrate in Part B, the title compound is obtained. Following the procedure of Example 7 except substituting ethyl 4 iodobutyrate for methyl iodide, the title compound is obtained. Following the procedure of Example 8 except substituting ethyl 5 iodovalerate for ethyl 4 iodobutyrate, the title compound is obtained. Following the procedure of Example 12 except substituting 1 heptenylcarboxylic acid for 1 decenylcarboxylic acid, and ethyl 5 iodovalerate for ethyl 4 iodobutyrate and eliminating the addition of dicyclohexylamine, the title compound is obtained. Following the procedure of Example 12 except substituting 1 nonenylcarboxylic acid for 1 decenylcarboxylic acid and eliminating the addition of dicyclohexylamine, the title compound is obtained. Following the procedure of Example 12 except substituting 1 undecenylcarboxylic acid for 1 decenylcarboxylic acid and ethyl 5 iodovalerate for ethyl 4 iodobutyrate and eliminating the addition of dicyclohexylamine, the title compound is obtained. Following the procedure of Example 12 except substituting 1 tridecenylcarboxylic acid for 1 decenylcarboxylic acid, and eliminating the addition of dicyclohexylamine, the title compound is obtained. Following the procedure of Example 12 except substituting 1 hexenylcarboxylic acid for 1 decenylcarboxylic acid, ethoxylamine hydrochloride for methoxylamine hydrochloride and ethyl 3 iodovalerate for ethyl 4 iodobutyrate, and eliminating the addition of dicyclohexylamine, the title compound is obtained. Following the procedure of Example 12 except substituting 1 octadecenylcarboxylic acid for 1 decenylcarboxylic acid and hexyloxylamine hydrochloride for methoxylamine hydrochloride, and eliminating the addition of dicyclohexylamine, the title compound is obtained. Following the procedure of Example 15 except substituting 1 dodecenylcarboxylic acid for 1 decenylcarboxylic acid, the title compound is obtained. Following the procedure of Example 15 except substituting 1 hexenylcarboxylic acid for 1 decenylcarboxylic acid, the title compound is obtained. Following the procedure of Example 15 except substituting 1 tetradecenylcarboxylic acid for 1 decenylcarboxylic acid, the title compound is obtained. Following the procedure of Example 15, except substituting 1 heptenylcarboxylic acid for 1 decenylcarboxylic acid, the title compound is obtained. Following the procedure of Example 13 except substituting 1 octenylcarboxylic acid for 1 decenylcarboxylic acid and methoxylamine hydrochloride for benzyloxylamine hydrochloride in Example 7 Part A , the title compound is obtained. Following the procedure of Example 13 except substituting 1 tridecenylcarboxylic acid for 1 decenylcarboxylic acid and ethoxylamine hydrochloride for benzyloxyamine hydrochloride in Example 7 Part A , the title compound is obtained. Following the procedure of Example 13 except substituting methoxylamine hydrochloride for benzyloxylamine hydrochloride in Example 7, Part A , the title compound is obtained. Following the procedure of Example 13 except substituting 1 undecenylcarboxylic acid for 1 decenylcarboxylic acid, the title compound is obtained. Following the procedure of Example 13 except substituting 1 nonadecenylcarboxylic acid for 1 decenylcarboxylic acid, the title compound is obtained. To a solution of compound prepared as described in Example 8 Part A 257 mg, 1 mmol in 6 ml of CH₃OH under argon is added pyridinium 4 toluenesulfonate 210 mg, 1.0 eq. . The mixture is heated to 55 C and stirred for 4 hours. The solution is diluted with ether and washed with ½ saturated sodium chloride 20 ml and brine 10 ml . The organic layer is dried over anhydrous MgSO₄ and reduced to yield a solid. Recrystallization from hexane EtOAc gives title compound. Following the procedure of Example 7 Part C except substituting the Example 73 compound for the Example 7 Part B compound, the title compound is obtained. Following the procedure of Example 73 except substituting 1 tridecenylcarboxylic acid for 1 decenylcarboxylic acid in Example 7, Part A, the title compound is obtained. Following the procedure of Example 6 except substituting allyl bromide for pentyl bromide, the title compound is obtained. Following the procedure of Example 3 except substituting N cyclohexylhydroxylamine hydrochloride for N phenylhydroxylamine hydrochloride, the title compound is obtained. Following the procedure of Example 3 except substituting 3 cyclohexylpropylcarboxylic acid for 3 phenylpropylcarboxylic acid in Part A, the title compound is obtained.